These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 14965314)
1. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Marathias KP; Agroyannis B; Mavromoustakos T; Matsoukas J; Vlahakos DV Curr Top Med Chem; 2004; 4(4):483-6. PubMed ID: 14965314 [TBL] [Abstract][Full Text] [Related]
2. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes. Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009 [TBL] [Abstract][Full Text] [Related]
3. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Vlahakos DV; Kosmas EN; Dimopoulou I; Ikonomou E; Jullien G; Vassilakos P; Marathias KP Am J Med; 1999 Feb; 106(2):158-64. PubMed ID: 10230744 [TBL] [Abstract][Full Text] [Related]
4. Recent changes in the landscape of combination RAS blockade. Epstein BJ; Smith SM; Choksi R Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020 [TBL] [Abstract][Full Text] [Related]
5. [Combined blockade of the renin-angiotensin system]. Azizi M Bull Acad Natl Med; 2014 Feb; 198(2):351-62; discussion 362. PubMed ID: 26263709 [TBL] [Abstract][Full Text] [Related]
6. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Naito M; Kawashima A; Akiba T; Takanashi M; Nihei H Am J Nephrol; 2003; 23(5):287-93. PubMed ID: 12897465 [TBL] [Abstract][Full Text] [Related]
7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences. Stergiou GS; Skeva II Curr Top Med Chem; 2004; 4(4):473-81. PubMed ID: 14965313 [TBL] [Abstract][Full Text] [Related]
9. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Lambers Heerspink HJ; Perkovic V; de Zeeuw D J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007 [TBL] [Abstract][Full Text] [Related]
10. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis. Salvador GL; Marmentini VM; Cosmo WR; Junior EL Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020 [TBL] [Abstract][Full Text] [Related]
13. [Angiotensin II receptor blockers: current status and future prospects]. Corvol P; Plouin PF Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389 [TBL] [Abstract][Full Text] [Related]
14. [The future of renin inhibition]. Uresin AY; Baran E Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475 [TBL] [Abstract][Full Text] [Related]
15. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Verdecchia P; Gentile G; Angeli F; Reboldi G Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743 [TBL] [Abstract][Full Text] [Related]
16. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial. Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578 [TBL] [Abstract][Full Text] [Related]
17. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade? Gerc V; Buksa M; Loza V; Kulic M Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117 [TBL] [Abstract][Full Text] [Related]
18. Blockade of the renin-angiotensin system. Cheung BM Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364 [TBL] [Abstract][Full Text] [Related]
19. Inhibiting the renin-angiotensin system: why and in which patients. Berra K; Miller NH J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897 [TBL] [Abstract][Full Text] [Related]
20. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Weber MA Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]